Skip to main content
Jin Li, MD, Neurology, Hawthorne, NY

JinLiMD

Neurology • Hawthorne, NY

Neuromuscular Medicine

Associate Professor, Neurology, New York Med Coll

Join to view full profile

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Li's full profile

Already have an account?

  • Office

    19 Bradhurst Ave, Suite 3850S
    Hawthorne, NY 10532
    Phone+1 914-345-1313
    Fax+1 914-345-5004

Summary

  • Dr. Jin Li is a neurologist in Hawthorne, NY and is affiliated with Westchester Medical Center. She received her medical degree from Beijing Medical University and has been in practice 24 years. She specializes in neuromuscular medicine and headache medicine.

Education & Training

  • Westchester Medical Center
    Westchester Medical CenterResidency, Neurology, 1999 - 2002
  • Westchester Medical Center
    Westchester Medical CenterInternship, Internal Medicine, 1998 - 1999
  • Beijing Medical University
    Beijing Medical UniversityClass of 1993

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2002 - 2025
  • OH State Medical License
    OH State Medical License Active through 2014
  • American Board of Psychiatry and Neurology Neurology
  • American Board of Psychiatry and Neurology Neuromuscular Medicine

Publications & Presentations

PubMed

Press Mentions

  • Nimotuzumab May Improve Overall Survival in Patients with KRAS Wild-Type Advanced Pancreatic Cancer
    Nimotuzumab May Improve Overall Survival in Patients with KRAS Wild-Type Advanced Pancreatic CancerJune 3rd, 2022
  • Yingli Pharma Announces Presentations on the Phase 1 Trials of Linperlisib, a PI3Kδ Selective Inhibitor, and YL-13027, an Oral TGFβR1 Inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting
    Yingli Pharma Announces Presentations on the Phase 1 Trials of Linperlisib, a PI3Kδ Selective Inhibitor, and YL-13027, an Oral TGFβR1 Inhibitor, at the American Society for Clinical Oncology 2021 Annual MeetingJune 4th, 2021
  • Henlius Plans to File the NDA of Novel Anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial Has Met the Primary Endpoint
    Henlius Plans to File the NDA of Novel Anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial Has Met the Primary EndpointMarch 29th, 2021
  • Join now to see all

Professional Memberships

Dr. Jin Li, Dr. Jin Li, MD, Dr. J Li